The global viral vector manufacturing market is projected to grow at a CAGR of 22.09% to reach a market size of US$1,469.144 million in 2025 from US$443.592 million in 2019.
The viral vector market is primarily being driven by the growing adoption of adenoviral vectors, lentiviral vectors, as well as retroviral vectors. The growing adoption stems from the need for effectively transferring therapeutic genes into the target cells that are an integral part of the process that involves the insertion of a functional copy of a gene into a defective cell one of the preferred treatment options for most chronic diseases, which is known as Gene therapy. The delivery of genetic payload into a patient cell to produce a therapeutic effect Viz retargeting of an immune cell to fight cancer or mutated gene correction. This technique opens the possibilities of investing in hemophilia and cancer thereafter achieving the cure of the disease by a single dose. Viral vectors have been utilized to treat a variety of diseases, that are inclusive of but limited to cardiovascular, different types of cancer, hematologic, infectious as well as metabolic diseases. Furthermore, the growing number of clinical trials, the increasing number of gene therapy, and the expanding cognizance of effective modes of disease treatment are further expected to drive the growth of the viral vector manufacturing market during the forecast period. Since vector designing, production, packaging, and release testing is subject to limited availability and faced with challenges due to the complex nature of technologies and platforms and thus many players in this space often endeavor in striking strategic collaboration and acquisitions that cover many aspects like the delivery of clinal grade product under its ambit, to facilitate the successful collaboration development of viral agent-based products.
Moreover, the efficient ability to express the therapeutic genes and non-pathogenic nature is another factor that is responsible for driving the growth of this market. The other key factors that are expected to drive the growth of the market are the increasing investment in biopharmaceutical production coupled with the growing aging population, healthcare expenditure, technological advancement, especially in the genetic engineering segment. Moreover, the increasing accessibility of healthcare facilities, the growing demand for treatment of disease due to the increasing global burden of diseases are a few of the other factors that are poised to drive the growth of this market during the forecast period. Nevertheless, the transitioning of this niche industry to high manufacturing is one such factor that may restrain the growth of the market to a certain extent.
Therefore, with such growing recognition of the importance of viral vectors, various developments are taking place in the viral vector manufacturing market. For instance, in June 2020, it was announced by Emergent BioSolutions Inc. (NYSE: EBS) which is a global life sciences company that it is going to invest $75 Million in Canton Site and expand viral vector and gene therapy capability facilitating the reinforcement of its contract development and manufacturing (CDMO) capabilities. Again, in June 2020, Oxford Biomedica (LSE: OXB) which is a major gene and cell therapy group, announced that it has signed an agreement of collaboration with the Vaccines Manufacturing and Innovation Centre (VMIC), a not-for-profit organization that has been established to provide the first strategic vaccine development and progressive manufacturing capability in the UK. Under this 5-year agreement, the organization will work towards enabling the manufacture of vaccines that are based on viral vector, to contribute towards a swift growth in the domestic capacity for this specialized field of vaccine manufacturing. In April 2020, Merck KGaA (FWB: MRK) a leading science and technology company announced that a € 100 million facility, second in Carlsbad, California USA that is intended to boost its BioReliance® viral and gene therapy service offering to help their customers to aid their customers to commercialize the gene therapies that are brought about by viral vectors concomitantly helping innovators scale up their production that is in tandem with the quantum that allows them to reach out to more patients. Earlier, in January 2020, the launch of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) in Germany was announced by bluebird bio, Inc. (Nasdaq: BLUE). ZYNTEGLO™ is a one-time gene therapy that has been specifically developed for patients aged 12 years and older with transfusion-dependent β-thalassemia (TDT) who do not possess the β0/β0 genotype. In December 2019, it was announced that a leading supplier of services and technologies for the life sciences industry called Novasep launched oXYgene™ which is a fully integrated offering for the construction of facilities dedicated towards customers to aid them in their viral vector production. In October 2019, it was reported that GE Healthcare Life Sciences which has now rebranded itself as Cytiva, was about to launch the KUBio™ box which is an adaptable, flexible and fully integrated environment for biomanufacturing to accelerate the production of gene therapies based on viral vector. These latest additions were intended to bring gene therapies swiftly to the market thereby contributing to the increased capacity in the viral vector area. In March 2018, it was reported that Sartorius Stedim Biotech S.A. (SSB), which is a major international technology partner supplier of products and services biopharmaceutical industry has been selected by ABL Europe as its chief supplier of single-use systems whereby the new viral vector manufacturing capacity has been started in Strasbourg at its European facility. ABL Europe, a subsidiary of ABL Inc. provides dedicated viral vector GMP manufacturing services for oncolytic, vaccine, and gene therapy projects in all stages of clinical development through to commercial launch.
|Market size value in 2019||US$443.592 million|
|Market size value in 2025||US$1,469.144 million|
|Growth Rate||CAGR of 22.09% from 2019 to 2025|
|Forecast Unit (Value)||USD Million|
|Segments covered||Type, Application, End-User, And Geography|
|Regions covered||North America, South America, Europe, Middle East and Africa, Asia Pacific|
|Companies covered||Sirion-Biotech GmbH, Vigene Biosciences Inc., Batavia Biosciences B.V., Virovek, Lonza, Vector Biolabs, Cobra Biologics, MaxCyte, Inc., Genelux, BioNTech SE|
|Customization scope||Free report customization with purchase|
Frequently Asked Questions (FAQs)
Vigene Biosciences Inc.
Batavia Biosciences B.V.
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.